New Delhi: United States President Donald Trump signed an executive order to speed up the review of new psychedelic drugs, including ibogaine, by the Food and Drug Administration. But the question remains—what is ibogaine and why is it so controversial?
While Trump is happy to quip about taking the psychedelics himself, the drug itself remains banned under the federal government’s most restrictive category for illegal drugs. However, Health Secretary Robert F Kennedy Jr had previously pledged to ease access to psychedelics for medical use. Since 1970, ibogaine has been designated as a Schedule I drug within the US, but clinics in both Canada and Mexico offer legal ibogaine treatments.
Ibogaine is a naturally occurring psychoactive alkaloid derived from the root of Tabernanthe iboga, a shrub native to Africa. It was traditionally used in Western African healing ceremonies, and in recent years, it has been tested to cure post-traumatic stress disorder (PTSD) and drug addiction.
Stanford Medicine researchers in 2024 found that ibogaine safely led to improvements in depression, anxiety and functioning among veterans with traumatic brain injuries.
“No other drug has ever been able to alleviate the functional and neuropsychiatric symptoms of traumatic brain injury. The results are dramatic,” said Nolan Williams, MD, an associate professor of psychiatry and behavioural sciences, who worked on the study.
Meanwhile, a study funded by the Austrian Science Fund found that ibogaine is anti-addictive in humans, as the drug alleviates drug craving.
“In the 1960’s, American and European self-help groups provided public testimonials that a single dose of ibogaine alleviated drug craving, opioid withdrawal symptoms, and prevented relapse for weeks, months and sometimes years,” found Deborah C Mash from the University of Miami.
Also Read: 25 years after 9/11—Trump’s new counter-terrorism doctrine reveals an exhausted America
Interest in the United States
In the US, the drug has gained popularity after it was endorsed by podcaster Joe Rogan, who joined the president at the Oval Office.
Rogan, a leading American podcaster, has been a strong advocate for psychedelics. At the event, he shared how he messaged Trump about the drug.
“Sounds great. Do you want FDA [Food and Drug Administration] approval? Let’s do it,” he shared the president’s quick response.
Trump’s executive order on the Department of Health and Human Services directs almost $50 million to states that have enacted or are developing programmes to advance psychedelic drugs for serious mental illness.
Marty Makary, commissioner of food and drugs, said that the FDA’s national priority vouchers will allow certain drugs to be approved quickly.
The FDA is also in the process of approving the first-ever human trials of ibogaine.
Trump’s order is expected to bring a flurry of investment to Gabon, where the traditional iboga treatment began.
Prior to Trump’s interest in the drug, Gabon was already garnering American interest. In January, Americans for Ibogain held a conference in Libreville, where Rogan appeared along with the group’s chief executive, W Bryan Hubbard.
Yann Guignon, president of Blessings Of The Forest, a Gabonese non-profit working to protect ibogo, who spoke to The Times, said that in Gabon, the reaction has been a “mix of pride, concern and frustration.”
“Some [foreign actors] are sincere and respectful, but others are opportunistic. There are increasing concerns about poaching, false healers, exploitation of traditional knowledge and the emergence of informal or predatory markets around iboga,” Guignon said.
(Edited by Insha Jalil Waziri)